期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌靶向治疗的一个新趋势：EML4-ALK融合基因

A new trend of targeted therapy in non-small cell lung cancer： EML4-ALK fusion gene
原文传递
导出
摘要 在非小细胞肺癌个体化治疗成为共识的今天，靶向治疗是其中的重要组成部分，EML4-ALK是近期发现的非小细胞肺癌的新的分子亚型。在亚洲、女性、无或轻度吸烟、肺腺癌患者中的高检出率及ALK抑制剂PF-02341066在Ⅰ期临床试验中显示出的良好疗效使EML4-ALK成为非小细胞肺癌又一靶向治疗点。 Individualized treatment in non-small cell lung cancer has reached a consensus today and targeted therapy is one of the important parts of it. EML4-ALK is a new molecular subtype discovered in non-small cell lung cancer cells. The high detection rate in patients who are Asian, female,with never or light smoking history, adenocarcinoma and the good curative effect of PF-02341066, a kind of ALK inhibitor in period Ⅰ clinical trials, make EML4-ALK be another targeted therapeutic target for non-small cell lung cancer.
作者 宗立国 陈余清 赵成岭
机构地区 蚌埠医学院附属医院呼吸内科
出处 《国际呼吸杂志》 2011年第21期1671-1676,共6页 International Journal of Respiration
关键词 非小细胞肺癌 EML4-ALK融合基因 靶向治疗 Non-small cell lung cancer EML4-ALK fusion gene Targeted therapy
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献46

  • 1Jemal A, Siegel R, Ward E,et al. Cancer statistics,2007. CA Cancer J C1in,2007,57:43- 66.
  • 2Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EMIA-ALK fusion gene in non-small-cell lung cancer. Nature, 2007,448 : 561-566.
  • 3Wong DW, Leung EL, So KK,et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer, 2009,115 : 1723-1733.
  • 4Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res, 2008,14 : 4275- 4283.
  • 5Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EMIA-ALK. J Clin Oncoi, 2009,27 : 4247- 4253.
  • 6Shiota M, Fujimoto J, Semba T,et al. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki 1 lymphoma cell line, AMS3. Oncogene, 1994, 9: 1567- 1574.
  • 7Morris SW, Naeve C, Mathew P, et al. ALK, the chromosome 2 gene locus altered by the t (2;5) in non- Hodgkin' s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) Oncogene, 1997,14:2175-2188.
  • 8Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis o{ cancer. Nat Rev Cancer, 2008,8 : 11 -23.
  • 9Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours:where are we now? J Clin Pathol, 2008, 61: 428- 437.
  • 10Li R, Morris SW. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev,2008,28:372-412.

二级参考文献17

  • 1Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev, 2004, 18:1926-1945.
  • 2Costa LJ. Aspects of roTOR biology and the use of roTOR inhibitors in non-Hodgkin' s lymphoma. Cancer Treat Rev, 2007, 33 :78 -84.
  • 3Panwalkar A, Vestovsek S, Glies FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer, 2004,100 : 657-666.
  • 4Ly C, Arechiga AF, Melo JV, et al. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res, 2003, 63: 5716-5722.
  • 5Bai RY, Ouyang T, Miething C,et al. Nucleophosmin-anaplastic lymphoma kinase associated with large-cell anaplastic lymphoma activates the phophatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood, 2000, 96: 4319-4327.
  • 6Jundt F, Raetzel N, Muller C, et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein { beta } and NF-{kappa} B activity in Hodgkin and anaplastic large cell lymphomas. Blood, 2005, 106 : 1801-1807.
  • 7Vega F, Medeiros LJ, Leventaki V, et al. Activation of mammalian target of Rapamycin signaling pathway contributes to tumor cell survival in anaplastic large cell lymphoma kinase-positive anaplatic large cell lymphoma. Cancer Res, 2006, 66: 6589-6597.
  • 8Marzec M, Kasprzycka M, Liu X, et al. Oneogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive roTOR signaling pathway. Oncogene, 2007, 26: 5606-5614.
  • 9Cruz R, Hedden L, Boyer D, et al. S6 kinase 2 potentiates interleukin-3-driven cell proliferation. J Leukoc Biol, 2005,78 : 1378- 1385.
  • 10Sekulic A, Hudson CC, Homme JL, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res, 2000, 60: 3504-3513.

共引文献4

国际呼吸杂志
2011年 第21期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部